Skye Bioscience Investors Pressed to Seek Lead Role in Securities Suit as Jan. 16 Deadline Nears
Investors who bought SKYE from Nov. 4, 2024 to Oct. 3, 2025 face a Jan. 16, 2026 cutoff to seek lead-plaintiff status over alleged misstatements about nimacimab.
